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Q&A with virologist Professor Urs Greber 
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FEBS Letters Editorial Office, Heidelberg University Biochemistry Center, Germany 
 
As the severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) continues to 
spread across the world, and the associated lung disease COVID-19 remains difficult to treat, 
information from media and private communication flows at high speed, often through 
unfiltered channels. Much of this information is speculative, as it derives from preliminary 
and inconclusive studies, and creates confusion as well as anxiety. This phenomenon was 
recently labelled as “infodemic” by the World Health Organization.  
 
We interviewed Dr Urs Greber, Professor of Molecular Cell Biology and Principle 
Investigator in Virology at the Department of Molecular Life Sciences of the University of 
Zurich, Switzerland, to answer some of the most controversial questions about SARS-CoV-2 
and set the facts straight. 
 
Where did this virus come from? 
Coronaviruses (CoVs) are endemic viruses in the human population. About 10-20% of the 
colds we get every year are due to coronaviruses, and they normally cause only minor 
problems. 
 
However, SARS-CoV-2 is clearly more infectious and deadly to humans than the other 
endemic coronaviruses. SARS-CoV-2 efficiently replicates in the upper respiratory tract, and 
can proceed into the lower respiratory tract where it exacerbates pre-existing lung conditions. 
It infects human cells when the S protein located on the surface of the coronavirus particle 
binds with high affinity to a protein exposed on the surface of the cells in the respiratory 
tract. Binding occurs through the receptor binding domain (RBD) of the S protein. SARS-
CoV-2, akin to several other coronaviruses, uses angiotensin-converting enzyme-2 (ACE-2) 
as an entry port into a lung cell [1].  
 
A recent publication discussed the available evidence on the emergence of SARS-CoV-2. It 
showed that SARS-CoV-2 emerged naturally, through a recombination of at least two 
viruses: a bat β-coronavirus (β-CoV) (genus Rhinolophus) and a pangolin β-CoV, neither of 
which normally infects humans [2]. The bat β-CoV is 96% similar to SARS-CoV-2, but it has 
a divergent receptor binding domain in the S protein (only 77% similar to SARS-CoV-2), and 
binds poorly to human ACE-2 (Scheme 1). This makes it unlikely to enter human cells. The 
pangolin β-CoV is only 90% similar to SARS-CoV-2, but the RBD of its S protein has 99% 
similarity with SARS-CoV-2 and it has high affinity to ACE-2 [3]. In fact, its affinity to 
ACE-2 is higher than that of the SARS-CoV-1 RBD, as indicated in two recent studies 
(Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A. & Li, F. 
(2020) Structural basis of receptor recognition by SARS-CoV-2, Nature. DOI: 
10.1038/s41586-020-2179-y. 
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L. & 
Wang, X. (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the 
ACE2 receptor, Nature. DOI: 10.1038/s41586-020-2180-5.) 
 
A likely scenario for the origin of SARS-CoV-2 is that the bat and the pangolin β-CoVs have 
infected one and the same organism (we do not know which one exactly), and their genes 
recombined, resulting in the insertion of the pangolin RBD into the S protein of the bat β-
CoV. The RBD from the pangolin virus has additional implications for the infectious nature 
of SARS-CoV-2. It harbours a furin enzyme cleavage site. Cleavage of the S protein at a 
furin cleavage site facilitates the entry of many viruses, including influenza viruses and CoVs 
into human cells. The importance of proteolytic cleavage at the furin cleavage site for the 
zoonotic transmission of viruses is in part based on experimental data with the MERS-like 
CoV from bats, which cannot efficiently enter human cells, unless small amounts of trypsin 
protease are added to the virion to mimic the furin cleavage of the S protein [4]. Interestingly, 
the ability of the S protein to be cleaved by the cellular furin protease is readily lost when 
CoVs are propagated in cell cultures, as shown with a feline CoV [5]. This implies that the 
acquisition of the furin cleavage site might be a gain of function for coronaviruses, but is lost 
when virus is amplified in cell cultures.   
 
Recombination typically requires the coexistence of at least two CoVs in a single infected 
cell, a situation which is favored by viral persistence, that is, the maintenance of viral 
genomes in infected cells over long periods of time. With CoVs this has been illustrated in a 
study, where scientists in Wuhan (China) analyzed the nucleotide sequences in feces from 
bats and found a range of novel coronaviruses with variable sequences from SARS-CoV-1 
indicative of massive rearrangements of CoV genomes in bats [6]. The emergence of SARS-
CoV by mutations, recombination and viral persistence has been discussed at length in the 
past [7]. 
 
On a broader scale, cross-species transmission events of coronaviruses is nothing new, and 
accounts for several animal and human diseases in the past 40 years due to bovine, canine, 
feline and porcine coronaviruses, as well as human coronavirus OC43 and human 
coronavirus 229E [7].  
 
Why is SARS-CoV-2 more infectious than most coronaviruses? 
Viral transmission is measured with the transmission factor, R0. To have a better idea, when 
R0<1 the virus will disappear from the population over time, whereas R0>2 means that the 
spread is exponential. One of the earliest hotspots of the virus was on the Diamond Princess 
cruise ship off the coast of Japan. A study performed on that ship showed that when social 
distancing was not implemented in the early phase of the epidemic, the transmission factor of 
SARS-CoV-2 was in the range of 15. This means that each infected person on the boat 
transferred the infection on average to 15 uninfected individuals. This is a very high 
transmission factor, similar to measles virus, and highlights the importance of social 
distancing in limiting the spread of the COVID-19 [8].  
 
Mechanistically, we do not know all the factors that contribute to the high transmissibility of 
SARS-CoV-2. The furin cleavage site in the S protein likely makes the virus more 
transmissible. There are a number of possible ways that furin cleavage can cause increased 
transmissibility: the S protein could more easily detach from the cells enhancing viral 
shedding into aerosols; it could enhance replication or assembly of the virus; or it could 
increase their replication in the upper respiratory tract, which makes the virus easily exhaled 
(i.e. it goes in the aerosols with high efficiency). 
 
SARS-CoV-2 appears to affect primarily elderly people. Why do children hardly 
develop severe symptoms? 
Statistics worldwide show that most of the deaths are among >65 year old people. Children 
are basically just as likely as adults to get infected and to transmit the virus to other people. 
However, they develop milder symptoms, or none at all, and the mortality rate is practically 
zero. This has been observed for other coronavirus infections, but it is very different from 
influenza virus infections, where young children and the elderly are usually more severely 
affected.  
 
No one really knows what protects children from coronaviruses. Possibly, T cell responses in 
children lead to a better elimination of the virus (perhaps also via induction of different B cell 
responses or higher titer of antibodies) or a different type of inflammatory response. There 
might be differences in the innate phase of the immune response as well, such as production 
of different cytokines. There might also be a difference in the level of ACE-2 expressed on 
lung cells between children and adults, or even the shedding of soluble ACE-2, which might 
inactivate SARS-CoV-2. Understanding why children have a better immune response to 
COVID-19 may help develop effective therapeutic strategies for infected adults. 
 
It appears that the severity of COVID-19 is different from one country to another and 
has increased over time. Is that true? 
A recent study conducted in Beijing sequenced 103 SARS-CoV-2 genomes and classified 
them into two groups, L and S, based on 2 nucleotide differences between them [9]. They 
claim that there are two ‘major types’ (L and S) of SARS-CoV-2 and that these types have 
different transmission rates. These and other claims in this study are, however, highly 
controversial (for discussion see [10]). There is no convincing evidence that these two 
mutations are associated with the severity of the disease. Unless reverse genetics is used to 
study the questionable mutations, correlations between genetic changes and phenotypic 
changes in the course of an epidemic or pandemic are indirect, and strong claims are not 
justified. 
 
Viruses replicate rapidly and accumulate mutations due to their error prone viral polymerase, 
which allows them to adapt to changes in the immune system or different tissues in an 
organism. Yet, the coronaviruses encode several accessory proteins which reduce the error 
rate to about 1 in 0.5-2 million bases [11, 12]. This means that only one out of 15-60 progeny 
viruses has a single point mutation in its genome. This is much lower than other RNA 
viruses, and renders coronaviruses genetically rather stable, unless they recombine their 
genomes with a related CoV. In addition, the vast majority of the mutations have no 
phenotype, they do not change viral infectivity. So, the good news is that SARS-CoV-2 has a 
low mutation rate (just 1 or 2 nucleotides a month, compared to 4 to 8 nucleotides a month in 
influenza virus). Therefore, it is highly unlikely that the circulating virus has mutated to a 
more aggressive phenotype from November 2019 to March 2020.  
 
Occasionally, mutations can be detrimental to viral infectivity. A study on SARS-CoV-1, the 
virus that caused the human pandemic in 2002-2003, showed that a deletion of 29 nucleotides 
in open reading frame 8 occurred along the initial human-to-human transmission chain. Cell 
culture experiments showed that this mutation caused a severe loss of fitness [13]. As the 29-
nucleotide deletion happened early on in the epidemics, it may have contributed to the 
disappearance of SARS-CoV-1 in 2003. Unfortunately, such a mutation may not help in 
resolving the current SARS-CoV-2 pandemic, as the wild type strain is highly prevalent. 
 
In conclusion, unfounded speculation about virulence increase of the circulating SARS-CoV-
2 can be detrimental to the community, as it confuses people, and accelerates irrational 
decision making. There is absolutely no evidence as far as I understand that SARS-CoV-2 
has become more aggressive in the course of the pandemic. Mortality rates may appear 
different due to different numbers of tests performed, different age groups tested, or different 
social behaviour between populations.  
 
How stable can coronavirus be on particular surfaces? 
Most studies on the stability of a virus on a surface are based on PCR, i.e. by detecting a 
small piece of intact viral genome. For example, biosafety officers that come to labs to take 
surface samples analyse them by PCR. A positive PCR result means that at least part of the 
virus is there, but this doesn’t mean that it is infectious. Eike Steinman and colleagues wrote 
a review on the persistence of coronaviruses on different types of surface materials [14]. 
Infection studies showed that CoV can remain infectious on glass, plastic, iron and paper for 
hours to even a few days. The studies were performed with non-SARS coronaviruses, but the 
results are likely to be similar for SARS-CoV-2. In any case, you can inactivate the virus 
with soap, especially alkaline soap, or high concentrations of ethanol (>60%). 
 
What therapeutic approaches are being explored to defeat COVID-19? 
A vaccine is definitely the best route as it can protect a large portion of the human population 
on an affordable basis. The low mutation rate of SARS-CoV-2 means that the chances of 
obtaining an effective and long-lasting vaccine are rather high. It will take 12-18 months to 
get the vaccine, however, unless someone finds a shortcut to make it faster. But shortcuts are 
dangerous since a vaccine failure may have devastating effects on society in terms of 
acceptance of vaccines in the future. We should only introduce a vaccine in humans after it 
has gone through animal trials, and we prove that it has anti-viral efficacy. 
 
Other therapeutic approaches involve the use of antivirals, such as Remdesivir, which is a 
nucleoside analogue that inhibits the replication of the viral genome. It works very well in 
cell culture against SARS-CoV-1 and SARS-CoV-2 [15, 16]. Other strategies explore the use 
of furin protease inhibitors. Researchers around the world are making strong efforts to 
prepare cocktails of monoclonal antibodies that can neutralise the virus. If this works it can 
be scaled up and used for patients with acute infection, in order to reduce the viral load. 
However, this approach is expensive and may be difficult to distribute because it involves 
biologicals which are subject to denaturation if stored improperly, or not kept in a cold chain. 
In addition, it is unclear how long-lasting the effects of antivirals can be, because drug 
resistant viruses will inevitably emerge. Nevertheless, direct anti-virals will be useful, as they 
buy time while patients develop immunity. 
 
Alternative approaches involve developing inhibitors that target physiological functions that 
are not viral, but cell-based, and are important for viral infectivity. For example, if we inhibit 
ACE-2, we can slow down viral entry. This of course will also inhibit the receptor’s 
physiological function, but researchers believe the body could tolerate the inhibition. Yet, 
viruses have been shown to be able to switch cell receptors in some cases. Receptor-targeting 
approaches might not be effective in the long run. Finally, doctors are using an IL6 receptor 
blocker, developed by Roche for treating rheumatoid arthritis. This drug basically inhibits the 
inflammatory response, easing out the symptoms in people who are heavily infected with 
lower respiratory disease. Whether an overshooting inflammatory response is a universal 
feature of lower respiratory tract SARS-CoV-2 infection remains to be seen. 
 
 
In summary, the COVID-19 outbreak is an indication of how difficult it is to handle 
emerging and reemerging infectious viruses. It teaches us the importance of accurate 
communication, constant surveillance, rapid diagnosis, and fundamental research on any 
aspect of virology. This will help us to better counteract the emergence of new pathogens in 
the future.  
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Scheme 1: Genetic relationship of the SARS-CoV-2 spike (S) protein to bat and 
pangolin sequences as well as SARS-CoV-1. 
The scheme highlights the recombination breakpoint in the S protein gene of SARS-CoV-2. 
SARS-CoV-2 is "very" similar to the Bat CoV RaTG13 S protein gene, except for the ACE-
2 receptor binding domain (RBD), which is more sililar to the pangolin CoV (analyses by 
Simplot). 
(A) Schematic representation of the SARS-CoV-2 genome, which is a single-stranded (ss) 
RNA of positive polarity (+) around 30kb, and codes for six open reading frames (ORFs) 
and accessory proteins.  
(B) Similarity plot analyses of different CoV S protein coding sequences. The SARS-CoV-2 
NCBI reference nucleotide sequence (NC045512) was used as query. Sequences of the S 
protein from different CoVs are indicated in brackets with their respective animal origin, 
strain name and NCBI accession numbers. The ACE-2 RBD coding region is framed with 
dotted lines. The pairwise similarity between all sequences in a multiple sequence 
alignment (ClustalW) was calculated with a 200-nt window moved along the sequence in 
10 nt steps using the software Simplot v3.5.1. The calculated RBD amino acid identity of 
the reference strain SARS-CoV-2 (NC045512) to the pangolin CoV (MT084071) is 98%. It 
has 78% identity (and 86% similarity) to the bat CoV RaTG13 (MN996532). Note the lower 
degree of similarity of the nucleotide sequences compared to the amino acid sequences.   
(C) Neighbour joining analysis of the RBD coding region. Evolutionary distances were 
calculated by the Kimura two-parameter method, with 1000 bootstrap replications to 
estimate node consistencies. The length of the branch is proportional to the number of 
nucleotide divergences. Sequences are labelled with their respective accession number, 
animal origin, coronavirus strain and location/date of isolation. The sequence of pangolin 
CoV has been derived from [1]. The scheme was conceived and crafted by Dr. Romain 
Volle, Department of Molecular Life Sciences, University of Zurich, Switzerland.  
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